Financial Performance - Company reported total revenue of 950 million yuan for Q1 2025, a year-on-year increase of 13.77% [1] - Net profit attributable to shareholders reached 111 million yuan, up 24.85% year-on-year [1] - Gross margin improved to 27.79%, reflecting an increase of 8.52% compared to the previous year [1] - Net margin also increased to 13.0%, showing a year-on-year growth of 12.0% [1] - Total expenses (selling, administrative, and financial) amounted to 79.34 million yuan, accounting for 8.35% of revenue, a decrease of 10.47% year-on-year [1] Key Financial Ratios - Return on Invested Capital (ROIC) for the previous year was 5.47%, indicating average capital returns [3] - Net profit margin for the previous year was 7.09%, suggesting average added value of products or services [3] - Cash flow situation is a concern, with cash and cash equivalents to current liabilities ratio at 58.26% [3] Shareholder Returns - Company has cumulatively raised 1.053 billion yuan since its listing and distributed 725 million yuan in dividends, resulting in a dividend-to-financing ratio of 0.69 [3] Operational Metrics - Earnings per share (EPS) for Q1 2025 was 0.19 yuan, a 26.67% increase year-on-year [1] - Book value per share increased to 6.1 yuan, up 4.47% from the previous year [1] - Operating cash flow per share was -0.19 yuan, a significant decrease of 318.76% year-on-year [1]

据证券之星公开数据整理，近期盟科药业（688373）发布2025年一季报。截至本报告期末，公司营业总 收入3321.7万元，同比上升0.61%，归母净利润-6163.25万元，同比上升39.66%。按单季度数据看，第一 季度营业总收入3321.7万元，同比上升0.61%，第一季度归母净利润-6163.25万元，同比上升39.66%。本 报告期盟科药业盈利能力上升，毛利率同比增幅2.58%，净利率同比增幅40.02%。 建议关注公司债务状况（有息资产负债率已达33.74%、近3年经营性现金流均值为负） 建议关注财务费用状况（近3年经营活动产生的现金流净额均值为负） 本次财报公布的各项数据指标表现尚佳。其中，毛利率84.53%，同比增2.58%，净利率-185.55%，同比 增40.02%，销售费用、管理费用、财务费用总计3713.51万元，三费占营收比111.8%，同比减26.18%， 每股净资产0.59元，同比减48.22%，每股经营性现金流-0.08元，同比增48.36%，每股收益-0.09元，同 比增43.75% | 项目 | 2024年一季报 | 2025年一季报 | 同比增幅 | | --- | -- ...

证券之星价投圈财报分析工具显示：业务评价：公司去年的ROIC为10.05%，资本回报率一般。去年的 净利率为3.73%，算上全部成本后，公司产品或服务的附加值不高。偿债能力：公司现金资产非常健 康。融资分红：公司上市16年以来，累计融资总额9.59亿元，累计分红总额1.68亿元，分红融资比为 0.17。商业模式：公司业绩主要依靠研发驱动。需要仔细研究这类驱动力背后的实际情况。 财报体检工具显示：建议关注公司现金流状况(货币资金/流动负债仅为58.75%)建议关注公司应收账款 状况(应收账款/利润已达492.96%) 分析师工具显示：证券研究员普遍预期2025年业绩在2.08亿元，每股收益均值在0.84元。 最近有知名机构关注了公司以下问题： 据证券之星公开数据整理，近期禾盛新材(002290)发布2025年一季报。截至本报告期末，公司营业总收 入6.27亿元，同比上升14.21%，归母净利润5095.13万元，同比上升82.72%。按单季度数据看，第一季 度营业总收入6.27亿元，同比上升14.21%，第一季度归母净利润5095.13万元，同比上升82.72%。本报 告期禾盛新材应收账款上升，应收账款同比增幅 ...